Stock BLUEJET BLUE JET HEALTHCARE LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Blue Jet Healthcare Limited Bombay S.E.

Equities

BLUEJET

INE0KBH01020

Pharmaceuticals

Delayed Bombay S.E.
Other stock markets
 06:00:54 2024-07-12 am EDT 		5-day change 1st Jan Change
424.2 INR +1.16% Intraday chart for Blue Jet Healthcare Limited -1.05% +15.26%
Jun. 30 Blue Jet Healthcare Limited Commissions Multi-Product Production Block at Ambernath, Maharashtra (Unit II) CI
May. 25 Blue Jet Healthcare Limited Recommends Final Dividend for the Financial Year Ended 31 March 2024 CI

Valuation

Fiscal Period: March 2024 2025 2026
Capitalization 1 72,786 - -
Enterprise Value (EV) 1 63,234 70,205 69,690
P/E ratio 40.6 x 31.5 x 25.7 x
Yield 0.26% 0.69% 1.29%
Capitalization / Revenue 9.33 x 7.26 x 5.84 x
EV / Revenue 8.89 x 7 x 5.6 x
EV / EBITDA 27.6 x 22.2 x 17.5 x
EV / FCF 92.5 x -189 x 99.9 x
FCF Yield 1.08% -0.53% 1%
Price to Book 7.86 x 7.04 x 5.81 x
Nbr of stocks (in thousands) 173,465 - -
Reference price 2 419.6 419.6 419.6
Announcement Date 5/25/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2023 2024 2025 2026
Net sales 1 - 7,116 10,029 12,453
EBITDA 1 - 2,292 3,158 3,980
EBIT 1 - 2,011 2,732 3,417
Operating Margin - 28.27% 27.24% 27.44%
Earnings before Tax (EBT) 1 - 2,201 3,069 3,799
Net income 1 1,600 1,638 2,282 2,905
Net margin - 23.01% 22.76% 23.32%
EPS 2 9.230 9.440 13.32 16.32
Free Cash Flow 1 - 684 -372 697.7
FCF margin - 9.61% -3.71% 5.6%
FCF Conversion (EBITDA) - 29.84% - 17.53%
FCF Conversion (Net income) - 41.77% - 24.02%
Dividend per Share 2 - 1.000 2.900 5.400
Announcement Date 7/10/23 5/25/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2024 Q4 2025 Q1
Net sales 1 2,032 1,879
EBITDA 1 649 522
EBIT 1 520 462
Operating Margin 25.6% 24.59%
Earnings before Tax (EBT) 1 593.5 516
Net income 1 417.5 381
Net margin 20.55% 20.28%
EPS 2 2.200 2.200
Dividend per Share - -
Announcement Date - -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2023 2024 2025 2026
Net Debt 1 - - - -
Net Cash position 1 - 3,186 2,581 3,096
Leverage (Debt/EBITDA) - - - -
Free Cash Flow 1 - 684 -372 698
ROE (net income / shareholders' equity) - 22.4% 27.9% 27%
ROA (Net income/ Total Assets) - 17.8% 19.8% 19.3%
Assets 1 - 9,197 11,542 15,041
Book Value Per Share 2 - 48.70 59.60 72.30
Cash Flow per Share - - - -
Capex 1 - 1,729 1,788 1,667
Capex / Sales - 24.29% 17.83% 13.38%
Announcement Date 7/10/23 5/25/24 - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
419.6 INR
Average target price
406.7 INR
Spread / Average Target
-3.08%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+60.25% 841B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+38.82% 625B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.49% 360B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.30% 327B
ABBVIE INC. Stock AbbVie Inc.
+9.64% 300B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.02% 242B
ROCHE HOLDING AG Stock Roche Holding AG
+3.76% 228B
NOVARTIS AG Stock Novartis AG
+18.18% 227B
AMGEN INC. Stock Amgen Inc.
+12.87% 174B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BLUEJET Stock
  4. BLUEJET Stock
  5. Financials Blue Jet Healthcare Limited